ArticleJournal of hepatocellular carcinoma2026
Nivolumab Plus Lenvatinib and Intra-Arterial Locoregional Therapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Real-World Study.
Shanzhi Gu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.